GlassScriptPhysician profile
Delatre Lolo
NPI 1790850030
$1,100.78
in general payments reported to CMS, 2019-2025
14 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.88 · 2020: $68.56 · 2021: $118 · 2022: $296 · 2023: $209 · 2024: $21.89 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $249.64 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $158.18 | 2022 | |
| Novo Nordisk INC | $140.46 | 2019-2022 | |
| Lilly USA, LLC | $127.85 | 2023 | |
| Novartis Pharmaceuticals Corporation | $88.18 | 2021-2024 | |
| Scpharmaceuticals INC. | $71.15 | 2025 | |
| Amgen INC. | $66.16 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.61 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $44.42 | 2021 | |
| Merck Sharp & Dohme LLC | $28.50 | 2022-2023 | Verquvo |
| Esperion Therapeutics, INC. | $23.60 | 2021 | |
| Irhythm Technologies, INC. | $23.54 | 2023 | Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $21.01 | 2019 | |
| Pfizer INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delatre Lolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.